Tian Da Pharmaceutical (00455.HK) announced its interim results, with a loss attributable to shareholders of HKD 32.25 million, a year-on-year decrease of 2.97%.

The Zhitong Finance APP reported that TianDa Pharmaceutical (00455.HK) announced its mid-term results for 2026, with revenue of approximately HKD 164 million, an increase of 20.19% year-on-year; the loss attributable to shareholders was HKD 32.25 million, a decrease of 2.97% year-on-year; and the loss per share was HKD 0.015.